Our paper on #polymutant SARS-CoV-2 spikes (led by Fabian Schmidt and Yiska Weisblum with @theodora_nyc and @NussenzweigL) now published in @Nature
nature.com/articles/s4158…
rdcu.be/cx5qM
It shows that plasma antibodies target numerous epitopes in SARS-CoV-2 spike such that ~TWENTY mutations are needed for neutralization escape from polyclonal antibodies elicited by infection or vaccination.
Notably, antibodies from those who had been BOTH infected AND later vaccinated (2x mRNA), neutralized the #polymutant and as well as diverse bat/pangolin sarbecoviruses and SARS-CoV
Thus, immune responses generated by infection or 2x mRNA vaccination alone do not come anywhere close to maximizing the capacity of human antibodies to neutralize SARS-CoV-2 variants and relatives
This, and the fact that vaccine efficacy is erroding means (IMO) that 'boosters' will/should be the norm for most of us at some point in the not-too-distant future.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Paul Bieniasz

Paul Bieniasz Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @PaulBieniasz

20 Jan
Our new preprint with @NussenzweigL @theodora_nyc and @bjorkmanlab

K417N, E484K and N501Y in SARS-CoV-2 “variants of concern” in UK, SA and Brazil are antibody escape mutations.
biorxiv.org/content/10.110…
Each confers resistance to commonly elicited RBD neutralizing antibodies cloned from mRNA vaccinees
Together, K417N, E484K and N501Y confer some (not complete) resistance to neutralization by vaccine recipient polyclonal plasma.
If we grow rVSV/SARS-CoV-2 with the cloned antibodies, most select for mutations at K417, E484 and/or N501.

Structures of vaccine-recipient antibodies with spike show K417, E484 or N501 are often in the epitopes of RBD-specific, vaccine elicited neutralizing antibodies
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(